Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study

2024.07.10 ｜抄読会論文

eClinical Medicine. 2024 Mar 22:70:102536. doi:10.1016/j.eclinm.2024.102536Title : Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade—a worldwide perspective

育成賞を受賞しました！

お知らせ

Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study

最近の投稿

カテゴリー

アーカイブ